HALO : Summary for Halozyme Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Halozyme Therapeutics, Inc. (HALO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.27+0.23 (+1.91%)
At close: 4:00PM EST
People also watch
ZIOPFOLDCLDXACADACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close12.04
Open11.84
Bid9.12 x 200
Ask12.75 x 400
Day's Range11.82 - 12.27
52 Week Range7.52 - 14.38
Volume1,223,230
Avg. Volume1,830,568
Market Cap1.58B
Beta2.34
PE Ratio (TTM)-22.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

    SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company ...

  • PR Newswire13 days ago

    MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20

    SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical stage immuno-oncology drug development company, today announced results from a pre-clinical study evaluating the potential benefits of using MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical trials for the treatment of metastatic pancreatic cancer with Halozyme Therapeutic's (HALO) investigational drug PEGPH20, which targets the tumor microenvironment potentially allowing increased access of co-administered cancer drug therapies to solid tumors.  PEGPH20 is currently in phase III clinical development for metastatic pancreatic cancer and in phase I clinical trials for non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Results from the preclinical study were positive demonstrating improvement in accumulation of MVT-5873 on tumors in an animal model of pancreatic cancer when administered in sequence with PEGPH20.

  • Why Halozyme Therapeutics, Inc. Jumped 15.6% in January
    Motley Fool24 days ago

    Why Halozyme Therapeutics, Inc. Jumped 15.6% in January

    Shares rose in response to the release of upbeat clinical data from an important phase 2 study.